Hologic (HOLX) has announced potential difficulties in achieving its 2026 milestone under the CVR agreement following a halt in shipments of its Brevera Breast Biopsy System Disposable 9 Gauge Needles. This decision came after an internal review revealed post-market issues. The company, sold to Blackstone and TPG for $18.3 billion, has a CVR allowing investors to earn up to $3 per share if certain sales targets are met by 2026 and 2027. However, the current shipping halt may impact these targets.
https://www.gurufocus.com/news/4086693/hologic-holx-faces-challenges-in-meeting-2026-cvr-milestone
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.